Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results